The study aimed to evaluate the effectiveness of plasma sCD14-ST (Presepsin) as an early diagnostic marker for sepsis in patients at a fever clinic in Beijing.
Researchers divided patients based on their Sequential Organ Failure Assessment (SOFA) scores into low and high risk for sepsis and measured various inflammatory biomarkers, including Presepsin.
Results showed that levels of Presepsin and procalcitonin were significantly higher in patients with high SOFA scores, indicating a potential for these markers to help identify sepsis early in patients presenting with fever.